FDA: Rapid Antigen COVID-19 Tests At Risk For False Positives
An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.
You may also be interested in...
The US FDA’s diagnostics chief says the agency isn’t seeing many submissions for rapid antigen tests, but is eager to authorize them.
In a potential game-changer in the ongoing fight to expand COVID-19 testing, the FDA has authorized a new kind of test that can be used by certain health care providers on-site to diagnose patients with the SARS-CoV-2 virus within minutes instead of days.
The head of the largest medical device lobby group told reporters the industry hopes to get 25 million diagnostic tests produced by the end of the month to fight the ongoing coronavirus pandemic in the US.